# PT-141 Dosage: The Approved Label, PK & Routes Studied

> PT-141 dosage as documented: the approved bremelanotide 1.75 mg subcutaneous label, half-life and pharmacokinetics, and the routes studied. Label figures only — no personal dosing advice.

The approved figure, the pharmacokinetics, the routes. Reported, not recommended.

## The short version

PT-141 dosage here means the numbers the approved label and the trials list — not a recommendation for anyone. The approved medicine, bremelanotide, has one labeled dose for its one approved use: 1.75 mg under the skin, taken as needed, no more than once in 24 hours and no more than 8 times a month [7].

The drug clears fast. Its terminal half-life (the time for blood levels to halve in the slow tail) is about 2.7 hours [7]. It peaks within about an hour [7].

Other doses appear only in research: dose-finding studies, early nasal work in men, and a short metabolic study. Those are study protocols, not instructions. A "PT-141 research chemical" is not the approved medicine and is not quality-controlled [7]. This page recommends no dose.

## PT-141 dosage — the approved label

The US prescribing information specifies, for the approved HSDD indication in premenopausal women, a 1.75 mg subcutaneous dose taken as needed at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month [7]. These are labeled figures for the approved drug, quoted as documentation — not a recommendation for any individual, and not applicable to off-label use.

## PT-141 dosage for women

The approved figure (1.75 mg subcutaneous, as-needed) is the dose studied in the premenopausal-HSDD population and carried in the label [7]. Phase 2 subcutaneous dose-finding in women evaluated 0.75, 1.25, and 1.75 mg before the 1.75 mg dose was selected [7]. These are trial and label figures, reported as such; this site recommends no dose for anyone.

## How long does PT-141 last

Per the US prescribing information, the terminal half-life after subcutaneous administration is approximately 2.7 hours (range 1.9-4.0 h) [7]. Median Tmax (time to peak concentration) is ~0.5-1.0 h [7]. Early intranasal studies reported a half-life of 1.85-2.09 h [7]. The fMRI data showed a desire effect persisting up to 24 hours despite the short plasma half-life, consistent with a central rather than concentration-locked action [5].

## Pharmacokinetics

Per the label: volume of distribution ~25.0 L; clearance ~6.5 L/hr; ~21% serum protein binding; metabolism by hydrolysis of the cyclic-peptide amide bonds and peptidase digestion; excretion 64.8% renal and 22.8% fecal from a radiolabeled dose [7]. The cyclic lactam structure confers greater stability than linear melanocortin peptides.

Routes studied: subcutaneous (the approved route); intranasal (early development, discontinued for PK variability); intravenous (early pharmacology) [7]. Other research doses on record — Phase 1 obesity work used subcutaneous up to 2.5 mg up to three times daily for 15 days [7] — are research protocols, not human-use guidance.

---

A magenta-circuit terminal reading of the PT-141 (bremelanotide) record — the one approved indication printed first, the label dose and trial figures echoed back verbatim, the off-label and unregulated-research-chemical lines traced in amber, and the community field reports fenced off as unverified; no clinic wired behind the console and nothing here dosed, sourced, prescribed, or sold.